title: Serotonin syndrome in maintenance haemodialysis patients following sertraline treatment for depression.
abstract: Sertraline, a selective serotonin reuptake inhibitor (SSRI), was used in a dose of 25 mg orally daily in 12 moderate to severely depressed patients of end stage renal disease (ESRD) on maintenance haemodialysis. Virtually all of them showed features of hyperserotonin state and in 11 drug was stopped within 3 weeks. One of the patients developed almost fatal serotonin syndrome and required intensive care with ventilatory support. In our experience the use of SSRI, sertraline for depression in ESRD patients on maintenance haemodalysis was associated with a high incidence of serotonergic side-effects and toxic serotonin syndrome.
authors: Department of Nephrology, Himalayan Institute Hospital Trust, Dehradun 248140.
authors: Whorra P
authors: WP
authors: Chander
authors: Navdeep
authors: N
authors: Singh
authors: Gulshan K
authors: GK
authors: Mukhiya
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003863:Depression / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000453:epidemiology / Q000523:psychology* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis; D020230:Serotonin Syndrome; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*; D020280:Sertraline / Q000627:therapeutic use*
chemical_list: D017367:Selective Serotonin Reuptake Inhibitors; D020280:Sertraline